A Study of ZN-c5 in Participants with Breast Cancer Study (H-46172)
A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
This study will evaluate the effect of different doses of ZN-c5, the study drug, on biomarkers in women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The results from this study will help define what an effective dose of this drug is for other patients in the future.
Participation in the study is expected to take up to 72 days from the beginning of screening to the last planned follow-up contact. Participants will receive study drug for 21 days before their planned surgery or non-surgical biopsy. During this time participants will have three to four office visits where assessments are performed by the study doctor and staff to monitor their health.
Participants in this study are eligible for reimbursement for their time and travel expenses.
More information on this study can be found at ClinicalTrials.gov.